GSK To Pay $3B To Settle US Avandia, Medicaid Probes
GlaxoSmithKline PLC has agreed to pay $3 billion to settle criminal and civil investigations by the U.S. government, including probes into its marketing of a controversial diabetes drug and possible abuses...To view the full article, register now.
Already a subscriber? Click here to view full article